REGENXBIO Webcast Highlights
REGENXBIO Inc. is preparing an engaging webcast that will focus on the AFFINITY DUCHENNE pivotal program and reveal the very first functional data deriving from the RGX-202 trial. Leading experts will discuss these promising developments, which could dramatically impact the treatment landscape for Duchenne muscular dystrophy.
Featuring Leading Experts
The event will showcase insights from recognized professionals in the field. Among the featured speakers is Aravindhan Veerapandiyan, M.D., who serves as the principal investigator for the AFFINITY DUCHENNE trial, a vital study exploring advanced treatment methodologies for Duchenne muscular dystrophy. Joining him will be Michael Kelly, PhD, the Chief Scientific Officer of CureDuchenne. Together, they will share the latest findings from this noteworthy clinical study.
About the Webcast
This informative session is set to take place on a Monday morning at 8:00 a.m. EST, making it easy for participants to join and catch the latest developments in gene therapy. Attendees will gain firsthand insights into the pivotal program of RGX-202 and learn about interim clinical data. Those interested can access the live webcast on REGENXBIO's website, ensuring a broader outreach for their innovative research and potential breakthroughs in therapy.
Presenting at Key Conferences
In addition to the webcast, the significant findings will be highlighted at esteemed conferences, including the American Society of Gene and Cell Therapy and the Muscular Dystrophy Association's upcoming gathering. These events are excellent opportunities for professionals and researchers to come together and discuss groundbreaking advancements in muscular dystrophy therapies.
About REGENXBIO Inc.
Founded in 2009, REGENXBIO has established itself as a leader in the development of gene therapies. The company’s focus lies in AAV Therapeutics—an innovative class of gene therapy capable of delivering transformative treatments for patients. With ongoing projects targeting neurological and retinal diseases, REGENXBIO aims to bring substantial improvements to the lives of patients suffering from rare genetic disorders.
Among its remarkable projects, RGX-202 stands out as an exploration into treating Duchenne muscular dystrophy. Additionally, the company is advancing ABBV-RGX-314, aimed at treating conditions such as wet age-related macular degeneration in partnership with AbbVie, and RGX-121 for the treatment of MPS II. Thousands of patients have benefitted from REGENXBIO's therapies, showcasing the promise of AAV Therapeutics in altering healthcare paradigms.
Corporate Communications and Investor Relations
For any queries regarding the webcast or for more corporate information, interested parties can get in touch with Dana Cormack from Corporate Communications. Furthermore, George E. MacDougall is available for inquiries on investor relations, ensuring that stakeholders receive timely updates regarding the company's progress and initiatives.
Frequently Asked Questions
What is the purpose of the REGENXBIO webcast?
The webcast focuses on discussing the AFFINITY DUCHENNE pivotal program and presenting the first functional clinical data from the ongoing RGX-202 trial.
Who are the featured speakers at the webcast?
The webcast will feature Aravindhan Veerapandiyan, M.D., and Michael Kelly, PhD, offering insights into their research and findings.
When is the webcast scheduled to take place?
The webcast is scheduled for a Monday at 8:00 a.m. EST.
Where can I access the webcast?
The live webcast will be accessible on REGENXBIO's official website in the Investors section.
What other events will showcase REGENXBIO's findings?
The findings from the RGX-202 trial will also be presented at major conferences such as the American Society of Gene and Cell Therapy.
